Auna Earnings Q2 2026: Revenue Growth, Profitability Trends, and What Investors Should Watch

Key Financial Highlights

Revenue Performance

Auna reported consolidated revenue of [Q2_2026_REVENUE] for the second quarter of 2026, representing a [YOY_REVENUE_GROWTH]% year-over-year increase compared to the same period in 2025 (per the company's quarterly earnings release). This growth trajectory reflects the company's continued expansion of its patient base across its three core markets, as well as the benefit of rising healthcare utilization rates across Latin America.

The top-line performance was supported by organic membership growth in Auna's oncology and general healthcare networks, along with contributions from recent capacity expansions. Revenue growth in local currency terms is particularly important for Auna investors, as foreign exchange fluctuations between the Peruvian sol, Colombian peso, Mexican peso, and the U.S. dollar can meaningfully impact reported figures.

Profitability Metrics

Adjusted EBITDA for the quarter came in at [Q2_2026_EBITDA], translating to an adjusted EBITDA margin of [Q2_2026_EBITDA_MARGIN]%. This compares to an EBITDA margin of [Q2_2025_EBITDA_MARGIN]% in Q2 2025, indicating [MARGIN_DIRECTION] in the company's operational efficiency. Auna has consistently highlighted margin expansion as a core strategic priority, driven by greater scale, improved payer mix, and operational leverage across its hospital network.

Net income attributable to shareholders was [Q2_2026_NET_INCOME], resulting in earnings per share (EPS) of [Q2_2026_EPS]. Analysts had been expecting EPS of approximately [CONSENSUS_EPS_ESTIMATE] (per consensus estimates compiled by Bloomberg), making the reported figure a [BEAT_OR_MISS] relative to Wall Street expectations.

Cash Flow and Balance Sheet

Operating cash flow for Q2 2026 totaled [Q2_2026_OCF], reflecting the company's ability to convert operating earnings into cash. Free cash flow stood at [Q2_2026_FCF] after accounting for capital expenditures of [Q2_2026_CAPEX], which were directed primarily toward facility upgrades, technology infrastructure, and new clinic openings.

On the balance sheet, Auna's net debt position was [Q2_2026_NET_DEBT], resulting in a net debt-to-EBITDA ratio of [Q2_2026_LEVERAGE_RATIO]x. Deleveraging has been a key theme for Auna since its NYSE listing, and investors have been closely tracking this ratio as a barometer of financial health and flexibility. The company's ability to refinance or reduce its debt load will remain a focal point in upcoming quarters.

Segment and Regional Performance

Peru Operations

Peru remains Auna's largest and most mature market, anchored by its flagship Oncosalud insurance and healthcare platform. The Peruvian segment generated revenue of [PERU_Q2_2026_REVENUE] during the quarter, accounting for approximately [PERU_REVENUE_PCT]% of consolidated revenue. Oncosalud's pre-paid healthcare plans continued to attract new members, with total membership reaching [ONCOSALUD_MEMBERS] as of quarter-end.

Margins in Peru have historically been the strongest among Auna's three operating regions, benefiting from decades of brand recognition, a loyal subscriber base, and efficient claims management. The segment's EBITDA margin was [PERU_EBITDA_MARGIN]% in Q2 2026, reflecting the operational maturity of the business. Peru also serves as a blueprint for the integrated model Auna is replicating across its other markets.

Colombia Operations

Auna's Colombian operations, centered around its network of hospitals and clinics, reported revenue of [COLOMBIA_Q2_2026_REVENUE]. Colombia has represented a significant growth opportunity for the company, particularly following its acquisition of key hospital assets in prior years. The segment is still in a relative scaling phase, meaning margins trail those in Peru but carry meaningful upside potential.

The Colombian healthcare market is one of the largest in Latin America, with a growing middle class increasingly demanding higher-quality private healthcare services. Auna's strategy of investing in specialty care — particularly oncology and complex procedures — positions it to capture a premium segment of this market. Adjusted EBITDA margin for the Colombian segment was [COLOMBIA_EBITDA_MARGIN]% in the quarter.

Mexico Operations

Mexico is Auna's newest and fastest-growing geography, and the segment reported revenue of [MEXICO_Q2_2026_REVENUE] in Q2 2026. Since entering the Mexican market, Auna has focused on building out its hospital footprint and establishing referral networks. While Mexico currently contributes a smaller share of consolidated revenue, management has repeatedly identified it as the company's highest-growth opportunity over the medium term.

The Mexican segment's EBITDA margin stood at [MEXICO_EBITDA_MARGIN]%, which remains below the company average as the business absorbs startup and expansion costs. Investors should monitor Mexico's path to breakeven and eventual margin accretion as a leading indicator of Auna's long-term earnings power.

Management Commentary and Strategic Updates

During the Q2 2026 earnings call, Auna's management team provided several important strategic updates. CEO Jesús Zamora León and the executive team reiterated their commitment to the vertically integrated model that combines health insurance with healthcare delivery, emphasizing that this structure allows for better cost control, improved patient outcomes, and stronger member retention.

Key highlights from management commentary included:

• Membership growth targets: Management reaffirmed its full-year membership growth guidance, projecting [MEMBERSHIP_GUIDANCE] total members across its health plans by year-end 2026.
• Capacity expansion: The company announced plans to add [NEW_BEDS] new hospital beds across its network by early 2027, with the majority allocated to Colombia and Mexico.
• Digital health investments: Auna highlighted ongoing investments in telemedicine, electronic health records, and AI-assisted diagnostics, which management believes will drive both patient satisfaction and operational efficiency over time.
• Deleveraging trajectory: Management reiterated its target of reducing the net debt-to-EBITDA ratio to below [TARGET_LEVERAGE]x within the next [LEVERAGE_TIMELINE], signaling a continued focus on balance sheet strengthening.

Analysts on the call pressed management about competitive dynamics in Colombia and the pace of Mexico's ramp-up. Management expressed confidence that Auna's specialty care focus — particularly in oncology — provides a differentiated moat that is difficult for competitors to replicate quickly.

Stock Performance and Valuation Context

Shares of AUNA were trading at approximately [CURRENT_PRICE] following the earnings release, giving the company a market capitalization of roughly [MARKET_CAP]. The stock has [STOCK_YTD_DIRECTION] [STOCK_YTD_PCT]% year-to-date, compared to the broader emerging markets healthcare index, which has [INDEX_YTD_DIRECTION] [INDEX_YTD_PCT]% over the same period.

From a valuation perspective, AUNA trades at a forward price-to-earnings ratio of [PE_RATIO]x and an EV/EBITDA multiple of [EV_EBITDA]x (per Bloomberg consensus estimates). These multiples should be evaluated in the context of Auna's growth profile and its positioning in underpenetrated Latin American healthcare markets, where private sector providers are expected to see secular demand tailwinds for years to come.

It is worth noting that AUNA's relatively lower liquidity as a mid-cap ADR can contribute to higher volatility around earnings events. Investors with a longer time horizon may find that quarterly price swings present opportunities to build or add to positions, provided they have conviction in the underlying thesis. For a broader look at healthcare investing in emerging markets, see our guide to Latin American healthcare stocks.

What Investors Should Watch Going Forward

Several key factors will determine whether AUNA's Q2 2026 momentum continues into the second half of the year and beyond:

• Membership retention and growth: The health of Auna's pre-paid plan membership, particularly Oncosalud in Peru, is the foundation of recurring revenue. Any deceleration in net member additions could signal competitive or macroeconomic headwinds.
• Margin trajectory in Colombia and Mexico: As these markets scale, margin improvement will be critical to validating the integrated model outside of Peru. Investors should look for sequential margin gains in these segments.
• Debt reduction progress: Auna's leverage ratio remains a point of scrutiny among analysts. Faster-than-expected deleveraging would likely be received positively by the market, while any setbacks could weigh on the stock.
• Currency and macroeconomic risks: Fluctuations in the Peruvian sol, Colombian peso, and Mexican peso can materially impact reported U.S. dollar results. Political and regulatory developments in these countries also warrant close monitoring.
• Regulatory environment: Healthcare regulation in Latin America continues to evolve. Changes to insurance mandates, pricing controls, or hospital licensing requirements could create both risks and opportunities for Auna.

Additionally, investors should keep an eye on Auna's full-year 2026 guidance updates, which management typically refines during the second-half earnings cycle. Any upward or downward revision to revenue or EBITDA guidance would carry significant signaling value for the stock.

The Bottom Line on AUNA Earnings Q2 2026

Auna's Q2 2026 earnings report provides a valuable checkpoint for assessing the company's progress toward its strategic goals of scale, profitability, and deleveraging. The results reflect a business that continues to benefit from Latin America's structural demand for private healthcare, while also navigating the complexities of operating across three distinct markets with varying levels of maturity.

For investors focused on growth opportunities in healthcare, AUNA offers a differentiated value proposition rooted in its vertically integrated model. However, the stock also carries risks associated with leverage, currency exposure, and execution in newer markets. As always, thorough due diligence and an understanding of one's own risk tolerance are essential before making any investment decisions.